Evidence map›Paper›PMID 39357559›Full record

ArticleThe journal of allergy and clinical immunology. In practice2025

Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting.

Jenny Huang, Leah H Puglisi, Kevin A Cook, John M Kelso, Hannah Wangberg

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07764159 (An Open-Label, Multicenter, Randomized Clinical Trial Evaluating the Efficacy and Safety of Oral Multi-Food Immunotherapy With Peanut and Tree Nuts Protein Mixtures), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07764159 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

An Open-Label, Multicenter, Randomized Clinical Trial Evaluating the Efficacy and Safety of Oral Multi-Food Immunotherapy With Peanut and Tree Nuts Protein Mixtures

TypeinterventionalSponsorMedical University of WarsawRan2026 to 2031Enrolled39ConditionsFood Allergies, Food Allergy in Children, Peanut Allergies, Tree Nut AllergiesArmsMulti-Food Oral Immunotherapy (Multi-OIT) with Peanut and Tree Nuts Proteins, Standard of Care (Elimination Diet)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Emergency Monitoring Following A Diagnosis of Anaphylaxis.Current allergy and asthma reports · 2025
    Review
  5. Oral Immunotherapy Should Play a Key Role in Preschool Food Allergy Management.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jenny HuangDivision of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
Leah H PuglisiScripps Department of Research & Development, Scripps Health, San Diego, Calif.
Kevin A CookDivision of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
John M KelsoDivision of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
Hannah WangbergDivision of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif. Electronic address: wangberg.hannah@scrippshealth.org.

Funding

Scripps Clinical and Translational Science HubUM1TR004407 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI Eric Jeffrey Topol · 2023 to 2026
$24.2M
NCATS NIH HHS UM1 TR004407
6 · The paper itself

Abstract

backgroundOral immunotherapy (OIT) for food allergy has been largely studied in older children within the context of clinical trials, and its availability has historically been limited for younger patients with food allergy. Data have shown that the most impact may actually be seen with the use of OIT in younger infants and toddlers.

objectiveTo evaluate the safety and feasibility of OIT in subjects 24 months and younger in a real-world setting using commercially available food products.

methodsThis was a retrospective study of subjects 24 months and younger initiated on OIT for peanut, tree nut, or sesame allergy within the Scripps Clinic allergy department. Medical records were reviewed for data regarding initial oral food challenges, OIT, and adverse outcomes.

resultsFifty-two subjects 24 months and younger were initiated on OIT. Most subjects (84.6%) were on single-food OIT, and some (15.4%) were on multifood OIT. No increased adverse outcomes were observed on multifood OIT. Of the 59 initial oral food challenges, objective reactions occurred during 42 challenges, most being low-grade reactions. During initial oral food challenges, 86.1% of peanut-allergic children tolerated 1/8 of 1 Bamba stick with no reaction. Most subjects (73.1%) updosed at home, and most (51.9%) had no reactions while updosing. Some had low-grade cutaneous reactions, none requiring epinephrine or emergency evaluation.

conclusionsOIT in infants is safe and feasible to perform in a real-world setting using commercially available food products with at-home updosing, thus increasing the availability of OIT for patients.

Indexed as

AllergensArachisDesensitization, ImmunologicFeasibility StudiesFood HypersensitivitySesamumAdministration, OralChild, PreschoolFemaleHumansInfantMaleNut HypersensitivityNutsPeanut HypersensitivityRetrospective StudiesAllergensAnaphylaxisFood allergyOral immunotherapyOral immunotherapy in infantsPeanut allergySesame allergyTree nut allergy

Identifiers

PMID39357559
PMCPMC11872170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.